BIOA (Bioage Labs) Cash-to-Debt : 40.71 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bioage Labs's cash to debt ratio for the quarter that ended in Dec. 2024 was 40.71.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Bioage Labs could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Bioage Labs's Cash-to-Debt or its related term are showing as below:

BIOA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41 Med: 11.2 Max: 40.71
Current: 40.71

During the past 3 years, Bioage Labs's highest Cash to Debt Ratio was 40.71. The lowest was 0.41. And the median was 11.20.

BIOA's Cash-to-Debt is ranked better than
83.99% of 1012 companies
in the Drug Manufacturers industry
Industry Median: 1.02 vs BIOA: 40.71

Bioage Labs Cash-to-Debt Historical Data

The historical data trend for Bioage Labs's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Bioage Labs Cash-to-Debt Chart

Bioage Labs Annual Data

Trend

Dec22

Dec23

Dec24

Cash-to-Debt

11.20

0.41

40.71

Bioage Labs Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial				0.41	13.18	13.58	32.75	40.71

Competitive Comparison of Bioage Labs's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioage Labs's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Bioage Labs's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Bioage Labs Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Bioage Labs's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	354.349	/	(6.202	+	2.502)
	=	40.71

Bioage Labs's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	354.349	/	(6.202	+	2.502)
	=	40.71

Bioage Labs (NAS:BIOA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Bioage Labs Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioage Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1445A South 50th Street, Richmond, CA, USA, 94804

Website

https://www.bioagelabs.com

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.